IRONWOOD PHARMA INC CLASS A (IRWD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for IRWD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IRWD | Chair | 61 | ["Former Chief Operating Officer, Endo Health Solutions, Inc.","CEO of Nora Therapeutics, Inc.","Company group chair for the worldwide virology business unit of Johnson & Johnson","President of Centocor, Inc.","Oversaw development and launches of several products, including Remicade®","Led marketing communications for gastrointestinal drug Prilosec® at Astra-Merck Inc.","Board member of Lantheus Holdings, Inc. and Xellia Pharmaceuticals ApS","Served on multiple boards including Aerie Pharmaceuticals, Inc., Trevena, Inc."] | ["Audit Committee","Governance and Nominating Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LNTH | LeadIndependentDirector; Chair | 61 | ["Strong commercial and operational management background", "Extensive experience in the pharmaceutical industry", "Former Chief Operating Officer, Endo Health Solutions, Inc.", "Former CEO, Nora Therapeutics, Inc.", "Former Company Group Chairperson for the Worldwide Virology business unit of Johnson & Johnson", "Former President, Centocor, Inc.", "Led marketing communications for gastrointestinal drug Prilosec\u00ae at Astra-Merck Inc."] | ["Chair", "Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Former Chief Operating Officer, Endo Health Solutions, Inc. Age: 61 Director since 2014 Board Committees Audit Committee Governance and Nominating Committee Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc. Before that she served as company group chair for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh overseeing the development and launches of several products, including Remicade (infliximab) and she was responsible for oversight of a research and development portfolio including compounds targeting autoimmune diseases, HIV, hepatitis C, and tuberculosis. Prior to joining Centocor, Inc., Ms. McHugh led marketing communications for gastrointestinal drug Prilosec (omeprazole) at Astra-Merck Inc. Ms. McHugh currently serves on the board of directors of Lantheus Holdings, Inc. (Nasdaq: LNTH), a public company, and Xellia Pharmaceuticals ApS, a privately held company. She also serves on the strategic advisory board for HealthCare Royalty Partners and the board of visitors for the Smeal College of Business of Pennsylvania State University. She previously served on the board of directors for Aerie Pharmaceuticals, Inc., Trevena, Inc., ViroPharma Inc., Epirus Biopharmaceuticals, Inc., Evelo Biosciences, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute. Ms. McHugh received her M.B.A. degree from St. Joseph s University and her B.S. degree from Pennsylvania State University. Ms. McHugh s experience as a chief executive officer and a chief operating officer at large multinational pharmaceutical companies makes her a valuable member of our board of directors. Her deep knowledge of Ironwood s history and strategy and strong relationships with our senior leadership team also make her a valuable resource.